$0.17
−10.61%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$0.16
From 52W high−99.99%
Volume16.78M
Market cap$2.32M
P/E (TTM)0.0x
P/S (TTM)0.0x
Div yield—
Key dataSep 18, 2026
Open
$0.16
From 52W high
−99.99%
Volume
16.78M
Market cap
$2.32M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
4.0x
P/E (TTM)
0.0x
RSI (14)
17.2
MomentumView details →
1D Return
−10.61%
YTD Return
−99.95%
SummaryUpdated Jun 1, 2026
Conduit Pharmaceuticals Inc. (NASDAQ:CDT) is a clinical-stage specialty biopharmaceutical company founded in 2019 and headquartered in San Diego, California. The company went public in March 2022 and operates as a subsidiary of Corvus Capital Limited. Conduit focuses on developing treatments for unmet medical needs in autoimmune diseases and male reproductive health, with a pipeline centered around two main drug candidates targeting conditions such as Hashimoto's thyroiditis and idiopathic male infertility.
Similar companies
Latest newsMore news →
CDT Equity Inc. issued a senior secured convertible promissory note with a total principal of $2,126,250 and 3,468,500 common stock purchase warrants to J.J. Astor & Co. in a private placement.2d agoCDT Equity Inc. issued a senior secured convertible promissory note to J.J. Astor & Co. in the principal amount of $541,620.16d agoJames Bligh was appointed Chief Executive Officer of CDT Equity Inc., effective 2026-08-31, succeeding Andrew Regan who resigned as CEO and director with severance of $50,000 per month for six months.19d ago